Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
121
-
Total 13F shares, excl. options
-
74.3M
-
Shares change
-
-6.44M
-
Total reported value, excl. options
-
$103M
-
Value change
-
-$10.5M
-
Put/Call ratio
-
0.28
-
Number of buys
-
50
-
Number of sells
-
-97
-
Price
-
$1.39
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2023
203 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2023.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 121 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 74.3M shares
of 207M outstanding shares and own 35.81% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (13.1M shares), ARMISTICE CAPITAL, LLC (9.19M shares), Point72 Asset Management, L.P. (4.98M shares), Meditor Group Ltd (4.4M shares), VANGUARD GROUP INC (4.26M shares), Bellevue Group AG (4.21M shares), PLATINUM INVESTMENT MANAGEMENT LTD (3.47M shares), MILLENNIUM MANAGEMENT LLC (3.35M shares), Two Seas Capital LP (2.94M shares), and Parkman Healthcare Partners LLC (2.13M shares).
This table shows the top 121 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.